Research on the pharmacological inhibition of METTL3 has found an impact on specific haematopoietic lineages in leukemia. This study appears to be part of broader advances in understanding the role of epitranscriptomics in hematopoiesis, both normal and malignant. The findings may have implications for the discovery of small-molecule drugs targeting cancer stem cells.